Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Exclusion Criteria

• •Subject has a primary diagnosis of PH other than Group 2 PH-HFpEF
• •Previous Percutaneous Coronary Intervention (PCI) or cardiac surgery (CABG), unless they have a negative stress test in the last 12 months)
• •Congenital heart disease
• •Clinically significant lung disease
• •Planned heart or lung surgery
• •Cardiac Index \>4.0 L/min/m2
• •Concomitant administration of pulmonary vasodilator therapy or taken within 14 days
• •Dialysis or Glomerular Filtration Rate (GFR) \<30 mL/min/1.73 m2
• •Liver dysfunction with Child-Pugh Class B or C
• •Evidence of systemic infection
• •Weight \> 150kg
• •Symptomatic systolic blood pressure (SBP) cannot be managed to ensure SBP \>100 mmHg
• •Heart rate \>= 100 bpm with the study drug, symptomatic and persistent for at least 10 minutes
• •Hemoglobin \< 80 g/L
• •Serum potassium \< 3.0 mmol/L or \> 5.5 mmol/L at baseline
• •Patients having severely compromised immune function
• •Pregnant, suspected to be pregnant, or breast-feeding